# Metformin as RenoProtector of Progressive Kidney Disease

Study · id `cardio:ct-nct03831464` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03831464](<https://clinicaltrials.gov/study/NCT03831464>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03831464

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 290 participants.

## Technical summary

Registry record NCT03831464. Randomized; quadruple masking; primary purpose treatment. Start 2019-11-05 (actual); primary completion 2024-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 290 participants (enrolled count; ClinicalTrials.gov record NCT03831464, source copy `cardio:ctgov-nct03831464-2023-12-19`, retrieved 2026-10-26)
- Started: 2019-11-05 (actual) (ClinicalTrials.gov record NCT03831464, source copy `cardio:ctgov-nct03831464-2023-12-19`, retrieved 2026-10-26)
- Primary completion: 2024-12-31 (anticipated) (ClinicalTrials.gov record NCT03831464, source copy `cardio:ctgov-nct03831464-2023-12-19`, retrieved 2026-10-26)
- Completion: 2024-12-31 (anticipated) (ClinicalTrials.gov record NCT03831464, source copy `cardio:ctgov-nct03831464-2023-12-19`, retrieved 2026-10-26)
- Countries: Belgium (ClinicalTrials.gov record NCT03831464, source copy `cardio:ctgov-nct03831464-2023-12-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03831464-2023-12-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Metformin as RenoProtector of Progressive Kidney Disease
- Acronym: RenoMet
- Condition: Chronic Kidney Diseases
- Intervention (Drug): Metformin Hydrochloride
- Intervention (Drug): Placebo Oral Tablet
- Lead sponsor: Universiteit Antwerpen
- Lead sponsor class: OTHER
- Collaborator: University Hospital, Antwerp
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Universiteit Antwerpen (`cardio:org-universiteit-antwerpen`)
- Registry lists this organization as a collaborator: University Hospital, Antwerp (`cardio:org-university-hospital-antwerp`)

## Provenance

Content hash: c47569f2ce51f43825a2ad2ad835b06b7ad1924b9cc96f4f80020853be2cf312
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
